References
1. Creutzig U, Zimmermann M, Reinhardt D, Dworzak M, Stary J,
Lehrnbecher T. Early deaths and treatment-related mortality in children
undergoing therapy for acute myeloid leukemia: analysis of the
multicenter clinical trials AML-BFM 93 and AML-BFM 98. Journal of
clinical oncology : official journal of the American Society of Clinical
Oncology . Nov 1 2004;22(21):4384-93. doi:10.1200/JCO.2004.01.191
2. Jastaniah W, Abrar MB, Khattab TM. Improved outcome in pediatric AML
due to augmented supportive care. Pediatric blood & cancer . Nov
2012;59(5):919-21. doi:10.1002/pbc.24195
3. Woods WG. Curing childhood acute myeloid leukemia (AML) at the
half-way point: promises to keep and miles to go before we sleep.Pediatric blood & cancer . May 1 2006;46(5):565-9.
doi:10.1002/pbc.20646
4. Flower A, Cairo MS. The evolution of allogeneic stem cell transplant
for children and adolescents with acute myeloid leukemia. Clin Adv
Hematol Oncol . Jan 2017;15(1):52-62.
5. Santos GW, Tutschka PJ, Brookmeyer R, et al. Marrow transplantation
for acute nonlymphocytic leukemia after treatment with busulfan and
cyclophosphamide. The New England journal of medicine . Dec 1
1983;309(22):1347-53. doi:10.1056/NEJM198312013092202
6. Nagler A, Rocha V, Labopin M, et al. Allogeneic hematopoietic
stem-cell transplantation for acute myeloid leukemia in remission:
comparison of intravenous busulfan plus cyclophosphamide (Cy) versus
total-body irradiation plus Cy as conditioning regimen–a report from
the acute leukemia working party of the European group for blood and
marrow transplantation. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology . Oct 1
2013;31(28):3549-56. doi:10.1200/JCO.2013.48.8114
7. Lee JH, Joo YD, Kim H, et al. Randomized trial of myeloablative
conditioning regimens: busulfan plus cyclophosphamide versus busulfan
plus fludarabine. Journal of clinical oncology : official journal
of the American Society of Clinical Oncology . Feb 20 2013;31(6):701-9.
doi:10.1200/JCO.2011.40.2362
8. Sora F, Grazia CD, Chiusolo P, et al. Allogeneic Hemopoietic Stem
Cell Transplants in Patients with Acute Myeloid Leukemia (AML) Prepared
with Busulfan and Fludarabine (BUFLU) or Thiotepa, Busulfan, and
Fludarabine (TBF): A Retrospective Study. Biology of blood and
marrow transplantation : journal of the American Society for Blood and
Marrow Transplantation . Apr 2020;26(4):698-703.
doi:10.1016/j.bbmt.2019.12.725
9. Shimomura Y, Hara M, Yamamoto H, et al. Adding melphalan to
fludarabine and a myeloablative dose of busulfan improved survival after
allogeneic hematopoietic stem cell transplantation in a propensity
score-matched cohort of hematological malignancies. Bone marrow
transplantation . Jul 2021;56(7):1691-1699.
doi:10.1038/s41409-021-01217-w
10. Lucchini G, Labopin M, Beohou E, et al. Impact of Conditioning
Regimen on Outcomes for Children with Acute Myeloid Leukemia Undergoing
Transplantation in First Complete Remission. An Analysis on Behalf of
the Pediatric Disease Working Party of the European Group for Blood and
Marrow Transplantation. Biology of blood and marrow
transplantation : journal of the American Society for Blood and Marrow
Transplantation . Mar 2017;23(3):467-474. doi:10.1016/j.bbmt.2016.11.022
11. Katsanis E, Sapp LN, Pelayo-Katsanis L, Whitney K, Zeng Y, Kopp LM.
Alternative Donor Hematopoietic Cell Transplantation Conditioned With
Myeloablative Busulfan, Fludarabine, and Melphalan is Well Tolerated and
Effective Against High-risk Myeloid Malignancies. Journal of
pediatric hematology/oncology . Nov 2016;38(8):e315-e318.
doi:10.1097/MPH.0000000000000621
12. Katsanis E, Maher K, Roe D, Simpson RJ. Progressive substitution of
post-transplant cyclophosphamide with bendamustine: A phase I study in
haploidentical bone marrow transplantation. eJHaem May 26, 2020
2020;1(1)(May 26):286-292. doi:10.1002/jha2.20
13. Katsanis E, Stea B, Kovacs K, et al. Feasibility and efficacy of
partially replacing post-transplant cyclophosphamide with bendamustine
in pediatric and young adult patients undergoing haploidentical bone
marrow transplantation. Transplant Cell Ther . Apr
20:S2666-6367(22)01230-1 2022;Apr 20:S2666-6367(22)01230-1;
10.1016/j.jtct.2022.04.015doi:10.1016/j.jtct.2022.04.015
14. Katsanis E, Sapp LN, Varner N, Koza S, Stea B, Zeng Y.
Haploidentical Bone Marrow Transplantation with Post-Transplant
Cyclophosphamide/Bendamustine in Pediatric and Young Adult Patients with
Hematologic Malignancies. Biology of blood and marrow
transplantation : journal of the American Society for Blood and Marrow
Transplantation . Oct 2018;24(10):2034-2039.
doi:10.1016/j.bbmt.2018.06.007
15. Katsanis E, Sapp LN, Reid SC, Reddivalla N, Stea B. T-Cell Replete
Myeloablative Haploidentical Bone Marrow Transplantation Is an Effective
Option for Pediatric and Young Adult Patients With High-Risk Hematologic
Malignancies. Front Pediatr . 2020;8:282.
doi:10.3389/fped.2020.00282
16. Jagasia MH, Greinix HT, Arora M, et al. National Institutes of
Health Consensus Development Project on Criteria for Clinical Trials in
Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging
Working Group report. Biology of blood and marrow transplantation
: journal of the American Society for Blood and Marrow Transplantation .
Mar 2015;21(3):389-401 e1. doi:10.1016/j.bbmt.2014.12.001
17. Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus Conference
on Acute GVHD Grading. Bone marrow transplantation . Jun
1995;15(6):825-8.
18. Clark JR, Scott SD, Jack AL, et al. Monitoring of chimerism
following allogeneic haematopoietic stem cell transplantation (HSCT):
technical recommendations for the use of short tandem repeat (STR) based
techniques, on behalf of the United Kingdom National External Quality
Assessment Service for Leucocyte Immunophenotyping Chimerism Working
Group. British journal of haematology . Jan 2015;168(1):26-37.
doi:10.1111/bjh.13073
19. Kaplan EL, Meier P. Nonparametric Estimation from Incomplete
Observations. Journal of the American Statistical Association .
1958/06/01 1958;53(282):457-481. doi:10.1080/01621459.1958.10501452
20. Peto R, Peto J. Asymptotically Efficient Rank Invariant Test
Procedures. Journal of the Royal Statistical Society Series A
(General) . 1972;135(2):185-207. doi:10.2307/2344317
21. Qayed M, Ahn KW, Kitko CL, et al. A validated pediatric disease risk
index for allogeneic hematopoietic cell transplantation. Blood .
Feb 18 2021;137(7):983-993. doi:10.1182/blood.2020009342
22. Kanda J, Horwitz ME, Long GD, et al. Outcomes of a 1-day
nonmyeloablative salvage regimen for patients with primary graft failure
after allogeneic hematopoietic cell transplantation. Bone marrow
transplantation . May 2012;47(5):700-5. doi:10.1038/bmt.2011.158
23. Katsanis E, Hennig T, Robinson JE, et al. Revisiting a single day
salvage conditioning following graft failure Bone marrow
transplantation . 2022;in press
24. Graetz R, Meyer R, Shehab K, Katsanis E. Successful resolution of
hyperammonemia following hematopoietic cell transplantation with
directed treatment of Ureaplasma parvum infection. Transpl Infect
Dis . Apr 2018;20(2):e12839. doi:10.1111/tid.12839
25. Sharma A, Huang S, Li Y, et al. Outcomes of pediatric patients with
therapy-related myeloid neoplasms. Bone marrow transplantation .
Dec 2021;56(12):2997-3007. doi:10.1038/s41409-021-01448-x
26. Kelly MJ, Horan JT, Alonzo TA, et al. Comparable survival for
pediatric acute myeloid leukemia with poor-risk cytogenetics following
chemotherapy, matched related donor, or unrelated donor transplantation.Pediatric blood & cancer . Feb 2014;61(2):269-75.
doi:10.1002/pbc.24739
27. Majhail NS, Brazauskas R, Hassebroek A, et al. Outcomes of
allogeneic hematopoietic cell transplantation for adolescent and young
adults compared with children and older adults with acute myeloid
leukemia. Biology of blood and marrow transplantation : journal of
the American Society for Blood and Marrow Transplantation . Jun
2012;18(6):861-73. doi:10.1016/j.bbmt.2011.10.031
28. Spitzer B, Jakubowski AA, Papadopoulos EB, et al. A
Chemotherapy-Only Regimen of Busulfan, Melphalan, and Fludarabine, and
Rabbit Antithymocyte Globulin Followed by Allogeneic T-Cell Depleted
Hematopoietic Stem Cell Transplantations for the Treatment of Myeloid
Malignancies. Biology of blood and marrow transplantation :
journal of the American Society for Blood and Marrow Transplantation .
Dec 2017;23(12):2088-2095. doi:10.1016/j.bbmt.2017.07.004
29. Edahiro T, Kawase T, Nagoshi H, et al. Allogeneic hematopoietic cell
transplantation using fludarabine plus myeloablative busulfan and
melphalan confers promising survival in high-risk hematopoietic
neoplasms: a single-center retrospective analysis. Hematology .
Dec 2021;26(1):186-198. doi:10.1080/16078454.2021.1881228
30. Srinivasan A, Raffa E, Wall DA, et al. Outcome of Haploidentical
Peripheral Blood Allografts Using Post-Transplantation Cyclophosphamide
Compared to Matched Sibling and Unrelated Donor Bone Marrow Allografts
in Pediatric Patients with Hematologic Malignancies: A Single-Center
Analysis. Transplant Cell Ther . Mar 2022;28(3):158 e1-158 e9.
doi:10.1016/j.jtct.2021.11.009
31. Symons HJ, Zahurak M, Cao Y, et al. Myeloablative haploidentical BMT
with posttransplant cyclophosphamide for hematologic malignancies in
children and adults. Blood Adv . Aug 25 2020;4(16):3913-3925.
doi:10.1182/bloodadvances.2020001648